FMP
Ampio Pharmaceuticals, Inc.
AMPE
AMEX
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.
0.0026 USD
0 (0%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. Michael A. Martino
sector
Healthcare
industry
Biotechnology
website
https://www.ampiopharma.comexchange
AMEX
Description
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged...
CIK
0001411906
ISIN
US03209T3077
CUSIP
03209T109
Address
373 Inverness Parkway
Phone
720 437 6500
Country
US
Employee
6
IPO Date
Mar 31, 2010
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
AMPE Financial Summary
CIK
0001411906
Exchange
AMEX
Industry
Biotechnology
Sector
Healthcare
CUSIP
03209T109
ISIN
US03209T3077
Country
US
Price
0
Beta
3.71
Volume Avg.
900
Market Cap
2.95k
Shares
-
52-Week
1.0E-4-2.91
DCF
15.97
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
0
P/B
-
Website
https://www.ampiopharma.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest AMPE News
It looks like there's no news available.
